Johnson & Johnson Unit Submits HIV Drug Candidate to FDA for Approval
July 20, 2007
On Wednesday, Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division said it had filed a new application for Food and Drug Administration approval of TMC125 (etravirine), its new HIV drug candidate. FDA's decision to fast-track TMC125 means the company can submit data as it becomes available, rather than all at once. The treatment for people infected with HIV-1 is meant to be administered with other antiretrovirals.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.